Gout drug Febuxostat useful for treatment of COVID-19

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2020-07-16 17:00 GMT   |   Update On 2020-07-16 17:00 GMT
Advertisement

Iran: Febuxostat (FBX) can be used as an alternative treatment to hydroxychloroquine (HCQ) for COVID-19 patients, suggests a recent study in the International Journal of Clinical Practice. FBX thus can be considered in patients with precaution or contraindication to HCQ.

 Febuxostat (FBX) is a novel non-purine xanthine oxidase (XO) approved for the treatment of hyperuricemia in patients with gout. It is already shown to have the anti-inflammatory, anti-oxidant, and anti-apoptosis effects of FBX.

Lotfollah Davoodi, Mazandaran University of Medical Sciences, Sari, Iran, and colleagues conducted this clinical trial to evaluate the effects of FBX versus HCQ on clinical symptoms, chest CT findings, and laboratory tests in outpatients having moderate symptoms of COVID-19 infection.

The clinical trial involved adult outpatients with moderate respiratory illness following COVID‐19 infection. They were randomly assigned to receive either FBX or HCQ for 5 days. Needs to hospitalization, clinical and laboratory data including fever, cough, breathing rate, C‐Reactive Protein level, lymphocytes count at the onset of admission, and was well as at 5 days of treatments were measured. In addition, CT findings were evaluated on admission and 14 days after initiation of treatment.

Sixty subjects were enrolled in the study with a 1 to 1 ratio in FBX and HCQ groups. 

Key findings of the study include:

  • On admission, fever (66.7%), cough (87%), tachypnea (44.4%), dyspnea (35%), elevated CRP value (94.4%) and lung involvement according to chest CT (100%) were documented in enrolled patients with insignificant difference between FBX and HCQ groups.
  • Fever, cough and tachypnea were significantly mitigated in both groups after five days of treatments without any significant differences between groups.
  • The mean percentages of lung involvement were significantly reduced to 7.3% and 8% after 14 days of treatment with FBX and HCQ, respectively.
  • In adult outpatients with moderate COVID‐19 infection, the effectiveness of FBX and HCQ was not different in terms of resolution of clinical manifestations, laboratory tests, and lung CT findings.

"This trial suggests that FBX is as an alternative treatment to HCQ for COVID‐19 infection and may be considered in patients with a contraindication or precaution to HCQ," concluded the authors. 

The study, "Febuxostat therapy in outpatients with suspected COVID‐19: A clinical trial," is published in the International Journal of Clinical Practice.

DOI: https://doi.org/10.1111/ijcp.13600

Tags:    
Article Source : International Journal of Clinical Practice

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News